ACTG Site Spotlight: BJGMC-JHU Clinical Research Site, Pune, India

Date: 05/13/2020

Publication:

ACTG Network Newsletter

The Byramjee Jeejeebhoy Government Medical College–Johns Hopkins University (BJGMC-JHU) research partnership was established in 2000 to conduct the multi-country Six Weeks Extended Nevirapine (SWEN) trial to reduce HIV transmission through breastfeeding. The results of that trial led to changes in the World Health Organization’s clinical care guidelines. Capitalizing on the team’s success and the infrastructure established, the research partnership continued and has grown exponentially. With clinical operations based at BJGMC in Pune, India, the BJGMC-JHU CRS is now a member of the Baltimore-Washington-India Clinical Trials Unit (BWI-CTU), which includes a CRS at Johns Hopkins University (Baltimore) and at Whitman-Walker Health (Washington, DC). ACTG trials represent a significant portion of our research portfolio. We’re proud that our work is improving disease outcomes for patients in our own community and around the world.

(Access Full Article)

Clinical Trials

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

Impact of Tuberculosis Infection on HIV-1 Antibody Response...

Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More